2010
DOI: 10.1016/j.canlet.2009.11.017
|View full text |Cite
|
Sign up to set email alerts
|

p21Cip1 Confers resistance to imatinib in human chronic myeloid leukemia cells

Abstract: Imatinib is a Bcr-Abl inhibitor used as first-line therapy of chronic myeloid leukemia (CML). p21(Cip1), initially described as a cell cycle inhibitor, also protects from apoptosis in some models. We describe that imatinib down-regulates p21(Cip1) expression in CML cells. Using K562 cells with inducible p21 expression and transient transfections we found that p21 confers partial resistance to imatinib-induced apoptosis. This protection is not related to the G2-arrest provoked by p21, a decrease in the imatinib… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
13
0

Year Published

2010
2010
2017
2017

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(14 citation statements)
references
References 36 publications
1
13
0
Order By: Relevance
“…GVS and other HDAC inhibitors have been shown to block cells in G1, at least in part through p21CDKN1A induction. Furthermore, p21CDKN1A has been observed to protect cells from apoptosis in most cellular contexts investigated, including chronic myeloid leukemia cells and myelomonocytic cells following HDAC inhibitor treatment [25][26][27][28], reviewed by Gartel and Tyner [29]. Thus, a lack of p21CDKN1A induction in the presence of HU may at least in part explain the increased apoptosis observed in the presence of both compounds.…”
Section: Discussionmentioning
confidence: 96%
“…GVS and other HDAC inhibitors have been shown to block cells in G1, at least in part through p21CDKN1A induction. Furthermore, p21CDKN1A has been observed to protect cells from apoptosis in most cellular contexts investigated, including chronic myeloid leukemia cells and myelomonocytic cells following HDAC inhibitor treatment [25][26][27][28], reviewed by Gartel and Tyner [29]. Thus, a lack of p21CDKN1A induction in the presence of HU may at least in part explain the increased apoptosis observed in the presence of both compounds.…”
Section: Discussionmentioning
confidence: 96%
“…In addition, autophagy regulates the ROS-mediated induction of the cell cycle inhibitor CDKN1A/p21 [28], which controls cellular proliferation, contributes to therapy resistance in cancer [29, 30] and controls phosphorylation of extracellular signal-regulated kinase MAPK1/ERK [31], which is a core regulator of p21 [32, 33]. …”
Section: Introductionmentioning
confidence: 99%
“…Under the posttranscriptional mechanism, stress-activated protein kinase p38 and JNK1 are involved in p21 stabilization [27]. On the other hand, p21 protects apoptosis in CML cells treated with imatinib [28]. As shown in previous studies, p21 has multiple functions according to stimulus; therefore, we need to clarify how JNK and p53-independent inducible p21 contribute to apoptosis progression to understand AI analog-inducible apoptosis mechanisms.…”
Section: Discussionmentioning
confidence: 95%
“…CML is characterized by the active bcr-abl kinase encoded by a fusion gene produced by a t(9;22) translocation [28]. Although imatinib is the main drug applied in CML treatment, and initial clinical results of imatinib in CML have been encouraging in terms of cytogenetic remission, patients in more advanced disease stages are either initially refractory to imatinib treatment or lose imatinib sensitivity over time and experience relapse [29][30][31].…”
Section: Discussionmentioning
confidence: 99%